[18] Semaglutide (Wegovy) is now available through NHS specialist weight management services for adults with at least one weight-related comorbidity and a BMI of 35 kg/m or above (or 32.5 kg/m for certain ethnic groups), as recommended in NICE TA875
All subjects brought their diary to every visit
The most commonly observed adverse events (incidence of 5% and twice that of placebo) were oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation and fecal incontinence
doi:10.1021/acs.jmedchem.5b00726 PMID:26308095 [4]Knudsen LB, Lau J
You are accepting unknown long-term exposure to a compound without long-term human safety data, in exchange for a benefit you have most likely already collected
Online convenience : UK pharmacies allow online ordering with a valid prescription